BioCentury
ARTICLE | Product Development

Regeneron leans into obesity with Phase II data

Additional dose ranging and longer term data necessary to address safety questions

June 4, 2025 12:24 AM UTC

Regeneron’s Phase II data for its myostatin and activin A inhibitors is the latest to demonstrate the lean mass lost from GLP-1 therapy and the ability of these mechanisms to improve the quality of weight loss from combination therapy. But the study also raises safety questions that can only be addressed with further data and studies.

In addition to the gastrointestinal side effects, one of the biggest drawbacks for the GLP-1R based obesity therapeutics is the high percentage of weight loss that comes from the reduction in lean mass. Companies have therefore been pursuing complementary mechanisms that can retain or enhance the weight loss of GLP-1R therapies while preserving lean mass and driving the majority of weight loss from fat mass...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article